处方时间过长是造成初级保健中抗生素使用不当的主要原因。

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES Infectious diseases now Pub Date : 2024-08-11 DOI:10.1016/j.idnow.2024.104962

Emmanuel Piednoir , Pascal Thibon , Marianne Delestre , Élise Fiaux , François Lebas , Renaud Verdon , Pierre Tattevin

{"title":"处方时间过长是造成初级保健中抗生素使用不当的主要原因。","authors":"Emmanuel Piednoir , Pascal Thibon , Marianne Delestre , Élise Fiaux , François Lebas , Renaud Verdon , Pierre Tattevin","doi":"10.1016/j.idnow.2024.104962","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>In France, 75% of systemic antibiotics are prescribed by general practitioners (GPs) in primary care. We aimed to estimate the burden of inappropriate use related to excessive prescription duration.</p></div><div><h3>Patients and methods</h3><p>In 2021, we performed a cross-sectional and pharmaco-economic study of a network of six GPs. The references for optimal durations were those of the French national guidelines for antibiotic prescription.</p></div><div><h3>Results</h3><p>Out of 196 antibiotic prescriptions, 33.7 % were of excessive duration, with a mean excess of 0.9 [0.86–0.94] to 1.6 [1.45–1.72] days per prescription. Ear, nose, and throat, respiratory tract, and skin and skin structure infections were the main infections associated with excessive prescription. The pharmaco-economic analysis showed that the cost of excessive prescription duration would range from an estimated 151 to 262 million € in France in 2021.</p></div><div><h3>Conclusion</h3><p>Addressing excessive antibiotic prescription duration by GPs may represent a powerful and cost-saving tool in antimicrobial stewardship programs.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 7","pages":"Article 104962"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001295/pdfft?md5=650b57687865e7aab7a51c4536e5a11d&pid=1-s2.0-S2666991924001295-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Excessive prescription duration is a major contributor of inappropriate antibiotic use in primary care\",\"authors\":\"Emmanuel Piednoir , Pascal Thibon , Marianne Delestre , Élise Fiaux , François Lebas , Renaud Verdon , Pierre Tattevin\",\"doi\":\"10.1016/j.idnow.2024.104962\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>In France, 75% of systemic antibiotics are prescribed by general practitioners (GPs) in primary care. We aimed to estimate the burden of inappropriate use related to excessive prescription duration.</p></div><div><h3>Patients and methods</h3><p>In 2021, we performed a cross-sectional and pharmaco-economic study of a network of six GPs. The references for optimal durations were those of the French national guidelines for antibiotic prescription.</p></div><div><h3>Results</h3><p>Out of 196 antibiotic prescriptions, 33.7 % were of excessive duration, with a mean excess of 0.9 [0.86–0.94] to 1.6 [1.45–1.72] days per prescription. Ear, nose, and throat, respiratory tract, and skin and skin structure infections were the main infections associated with excessive prescription. The pharmaco-economic analysis showed that the cost of excessive prescription duration would range from an estimated 151 to 262 million € in France in 2021.</p></div><div><h3>Conclusion</h3><p>Addressing excessive antibiotic prescription duration by GPs may represent a powerful and cost-saving tool in antimicrobial stewardship programs.</p></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"54 7\",\"pages\":\"Article 104962\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666991924001295/pdfft?md5=650b57687865e7aab7a51c4536e5a11d&pid=1-s2.0-S2666991924001295-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991924001295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991924001295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的：在法国，75%的全身用抗生素是由全科医生（GP）在基层医疗机构开出的处方。我们旨在估算与处方时间过长有关的不当使用所造成的负担：2021 年，我们对一个由六名全科医生组成的网络进行了横断面和药物经济学研究。最佳用药时间参考了法国国家抗生素处方指南：在 196 份抗生素处方中，33.7% 的处方时间过长，平均每份处方超过 0.9 [0.86-0.94] 天至 1.6 [1.45-1.72] 天。耳鼻喉、呼吸道以及皮肤和皮肤结构感染是与处方过量有关的主要感染。药物经济学分析表明，到 2021 年，法国因处方时间过长而造成的损失估计为 1.51 亿至 2.62 亿欧元：结论：在抗菌药物管理计划中，解决全科医生开具抗生素处方时间过长的问题可能是一个强有力且可节约成本的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Excessive prescription duration is a major contributor of inappropriate antibiotic use in primary care

Objectives

In France, 75% of systemic antibiotics are prescribed by general practitioners (GPs) in primary care. We aimed to estimate the burden of inappropriate use related to excessive prescription duration.

Patients and methods

In 2021, we performed a cross-sectional and pharmaco-economic study of a network of six GPs. The references for optimal durations were those of the French national guidelines for antibiotic prescription.

Results

Out of 196 antibiotic prescriptions, 33.7 % were of excessive duration, with a mean excess of 0.9 [0.86–0.94] to 1.6 [1.45–1.72] days per prescription. Ear, nose, and throat, respiratory tract, and skin and skin structure infections were the main infections associated with excessive prescription. The pharmaco-economic analysis showed that the cost of excessive prescription duration would range from an estimated 151 to 262 million € in France in 2021.